Neuronal cell death in Huntington's disease: a potential role for dopamine.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Trends in Neurosciences

• Publication date

  2000-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0166-2236(00)01568-XPMID 10838590
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dopamine D1 receptor number — a sensitive PET marker for early brain degeneration in Huntington's disease

  2005cited by this paper
• Nature and distribution of brain lesions in rats intoxicated with 3-nitropropionic acid: A type of hypoxic (energy deficient) brain damage

  2004cited by this paper
• Enhanced sensitivity to N‐methyl‐D‐aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease

  1999cited by this paper
• Forskolin and dopamine D1 receptor activation increase huntingtin's association with endosomes in immortalized neuronal cells of striatal origin.

  1999cited by this paper
• Malonate‐Induced Generation of Reactive Oxygen Species in Rat Strium Depends on Dopamine Release but Not on NMDA Receptor Activation

  1999cited by this paper
• Clorgyline and deprenyl attenuate striatal malonate and 3-nitropropionic acid lesions.

  1999cited by this paper
• Biochemical abnormalities and excitotoxicity in Huntington's disease brain

  1999cited by this paper
• Catecholamines Potentiate Amyloid β-Peptide Neurotoxicity: Involvement of Oxidative Stress, Mitochondrial Dysfunction, and Perturbed Calcium Homeostasis

  1998cited by this paper
• Dopaminergic modulation of early signs of excitotoxicity in visualized rat neostriatal neurons

  1998cited by this paper
• Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances.

  1998cited by this paper
• 6-Hydroxydopamine injections into the nigrostriatal pathway attenuate striatal malonate and 3-nitropropionic acid lesions.

  1998cited by this paper
• Partial Inhibition of Brain Succinate Dehydrogenase by 3‐Nitropropionic Acid Is Sufficient to Initiate Striatal Degeneration in Rat

  1998cited by this paper
• Dopamine Modulates the Susceptibility of Striatal Neurons to 3-Nitropropionic Acid in the Rat Model of Huntington’s Disease

  1998cited by this paper
• Review Article Reciprocaldopamine-glutamatemodulation of release in the basalganglia

  1998cited by this paper
• Reciprocal dopamine-glutamate modulation of release in the basal ganglia.

  1998cited by this paper
• Increased Vulnerability to 3‐Nitropropionic Acid in an Animal Model of Huntington's Disease

  1998cited by this paper
• Toxicity of Dopamine to Striatal Neurons In Vitro and Potentiation of Cell Death by a Mitochondrial Inhibitor

  1998cited by this paper
• Neurotoxicity of endogenous cysteinylcatechols.

  1997cited by this paper
• The effect of dopamine depletion on the H2O2 production in the rat striatum following transient middle cerebral artery occlusion.

  1997cited by this paper
• Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow.

  1997cited by this paper
• Inhibition of Glutamate Transport in Synaptosomes by Dopamine Oxidation and Reactive Oxygen Species

  1997cited by this paper
• Mitochondrial respiratory chain function in multiple system atrophy

  1997cited by this paper
• Mitochondria and free radicals in neurodegenerative diseases

  1997cited by this paper
• Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine.

  1997cited by this paper
• Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia

  1997cited by this paper
• Energy metabolism defects in Huntington's disease and effects of coenzyme Q10

  1997cited by this paper
• Metabolic inhibition enhances selective toxicity of L-DOPA toward mesencephalic dopamine neurons in vitro.

  1997cited by this paper
• Dopaminergic modulation of excitatory postsynaptic currents in rat neostriatal neurons.

  1997cited by this paper
• PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease.

  1997cited by this paper
• Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.

  1997cited by this paper
• Mechanisms of dopamine-induced cell death in cultured rat forebrain neurons: interactions with and differences from glutamate-induced cell death.

  1997cited by this paper
• Age-related increases in brain monoamine oxidase B in living healthy human subjects.

  1997cited by this paper
• Levodopa induces apoptosis in cultured neuronal cells—A possible accelerator of nigrostriatal degeneration in Parkinson's disease?

  1997cited by this paper
• Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease.

  1996cited by this paper
• Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons.

  1996cited by this paper
• Minireview. Emerging new functions of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in mammalian cells.

  1996cited by this paper
• Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH

  1996cited by this paper
• Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases.

  1996cited by this paper
• Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington’s Disease

  1996cited by this paper
• l‐DOPA Up‐Regulates Glutathione and Protects Mesencephalic Cultures Against Oxidative Stress

  1996cited by this paper
• Mitochondrial defect in Huntington's disease caudate nucleus

  1996cited by this paper
• Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections.

  1996cited by this paper
• Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease

  1996cited by this paper
• Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.

  1996cited by this paper
• Mitochondrial Depolarization in Glutamate-Stimulated Neurons: An Early Signal Specific to Excitotoxin Exposure

  1996cited by this paper
• Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study.

  1995cited by this paper
• 3‐Nitropropionic Acid Neurotoxicity Is Attenuated in Copper/Zinc Superoxide Dismutase Transgenic Mice

  1995cited by this paper
• Dopamine Neurotoxicity: Inhibition of Mitochondrial Respiration

  1995cited by this paper
• Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency

  1995cited by this paper
• The role of N-methyl-D-aspartate receptors in the regulation of physiologically released dopamine.

  1995cited by this paper
• Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients

  1995cited by this paper
• Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate

  1995cited by this paper
• Dopamine-induced protection of striatal neurons against kainate receptor-mediated glutamate cytotoxicity in vitro.

  1994cited by this paper
• L-dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity?

  1994cited by this paper
• Nitric oxide inhibits [3H]dopamine uptake.

  1994cited by this paper
• Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia

  1994cited by this paper
• Ubisemiquinones as obligatory intermediates in the electron transfer from NADH to ubiquinone.

  1994cited by this paper
• Superoxide and peroxynitrite inactivate aconitases, but nitric oxide does not.

  1994cited by this paper
• Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues

  1993cited by this paper
• Inhibition of Succinate Dehydrogenase by Malonic Acid Produces an “Excitotoxic” Lesion in Rat Striatum

  1993cited by this paper
• The High Sensitivity to Rotenone of Striatal Dopamine Uptake Suggests the Existence of a Constitutive Metabolic Deficiency in Dopaminergic Neurons From the Substantia Nigra

  1993cited by this paper
• Age‐Dependent Striatal Excitotoxic Lesions Produced by the Endogenous Mitochondrial Inhibitor Malonate

  1993cited by this paper
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

  1993cited by this paper
• Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid

  1993cited by this paper
• Alternative excitotoxic hypotheses

  1992cited by this paper
• Increased Cerebrospinal Fluid Dopamine and 3,4‐Dihydroxyphenylacetic Acid Levels in Huntington's Disease: Evidence for an Overactive Dopaminergic Brain Transmission

  1992cited by this paper
• Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?

  1992cited by this paper
• Reactive Oxygen Species and the Central Nervous System

  1992cited by this paper
• L-glutamate-evoked release of dopamine from synaptosomes of the rat striatum: involvement of AMPA and N-methyl-D-aspartate receptors.

  1992cited by this paper
• Nigrostriatal pathway modulates striatum vulnerability to quinolinic acid.

  1991cited by this paper
• Dopaminergic modulation of excitotoxicity in rat striatum: Evidence from nigrostriatal lesions

  1991cited by this paper
• 2,4,5-Trihydroxyphenylalanine (6-hydroxy-dopa) displaces [3H]AMPA binding in rat striatum.

  1991cited by this paper
• Heterogeneous dopamine receptor changes in early and late Huntington's disease.

  1991cited by this paper
• 2,4,5-trihydroxyphenylalanine in solution forms a non-N-methyl-D-aspartate glutamatergic agonist and neurotoxin.

  1991cited by this paper
• Nigral dopamine type-1 receptors are reduced in Huntington's disease: a postmortem autoradiographic study using [3H]SCH 23390 and correlation with [3H]forskolin binding.

  1990cited by this paper
• Chemically induced hypoglycemia and anoxia: relationship to glutamate receptor-mediated toxicity in retina.

  1990cited by this paper
• D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.

  1990cited by this paper
• Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson's and Huntington's diseases.

  1990cited by this paper
• In Vivo Autoxidation of Dopamine in Guinea Pig Striatum Increases with Age

  1990cited by this paper
• Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture

  1990cited by this paper
• Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease.

  1990cited by this paper
• Deprenyl suppresses the oxidant stress associated with increased dopamine turnover

  1989cited by this paper
• Coupling of D1 dopamine receptors to the guanine nucleotide binding protein Gs is deficient in Huntington's disease.

  1989cited by this paper
• Excitotoxicity of NMDA and kainic acid is modulated by nigrostriatal dopaminergic fibres.

  1989cited by this paper
• Dopamine turnover and glutathione oxidation: implications for Parkinson disease.

  1989cited by this paper
• Ptosis and supranuclear downgaze paralysis

  1989cited by this paper
• Anatomic correlation of NMDA and 3H-TCP-labeled receptors in rat brain

  1988cited by this paper
• Organization of dopamine D1 and D2 receptors in human striatum: Receptor autoradiographic studies in Huntington's disease and schizophrenia

  1988cited by this paper
• Exposure of striatal [corrected] synaptosomes to L-dopa increases levels of oxidized glutathione.

  1988cited by this paper
• Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced.

  1988cited by this paper
• Defect in succinate oxidation by isolated muscle mitochondria in a patient with symmetrical lesions in the basal ganglia.

  1988cited by this paper
• NMDA receptor losses in putamen from patients with Huntington's disease.

  1988cited by this paper
• Catecholamine toxicity in cerebral cortex in dissociated cell culture

  1988cited by this paper
• Differential loss of striatal projection neurons in Huntington disease.

  1988cited by this paper
• Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain.

  1987cited by this paper
• Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum

  1987cited by this paper
• Amino acid neurotransmitter abnormalities in Huntington's disease and the quinolinic acid animal model of Huntington's disease.

  1987cited by this paper
• Modulatory Effect of Dopamine on High‐Affinity Glutamate Uptake in the Rat Striatum

  1987cited by this paper
• Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease.

  1987cited by this paper
• Substantia nigra lesion protects against ischemic damage in the striatum.

  1987cited by this paper

• Amyloid‐Inducing Agents via Metabolite Self‐Assembly Expands the Boundary of Prion Concept beyond Proteins

  2025cites this paper
• Impact of the Ketogenic Diet on Neurological Diseases: A Review

  2025cites this paper
• Influence of dietary patterns in the pathophysiology of Huntington's Disease: A literature review

  2024cites this paper
• Computational Assessment of the Phytochemicals of Panax ginseng C.A. Meyer Against Dopamine Receptor D1 for Early Huntington’s Disease Prophylactics

  2024cites this paper
• Ödül Değerinde Kimyasal Dopamin ve İşlevleri

  2024cites this paper
• Dopamine Pharmacodynamics: New Insights

  2024cites this paper
• Microglia-mediated neuron death requires TNF and is exacerbated by mutant Huntingtin.

  2024cites this paper
• Catechol oxidase nanozyme based colorimetric sensors array for highly selective distinction among multiple catecholamines.

  2023cites this paper
• Multi‐Scale Label‐Free Human Brain Imaging with Integrated Serial Sectioning Polarization Sensitive Optical Coherence Tomography and Two‐Photon Microscopy

  2023cites this paper
• Dopamine in the Regulation of Glucose Homeostasis, Pathogenesis of Type 2 Diabetes, and Chronic Conditions of Impaired Dopamine Activity/Metabolism: Implication for Pathophysiological and Therapeutic Purposes

  2023cites this paper
• Discovery of CVN417, a Novel Brain-Penetrant α6-Containing Nicotinic Receptor Antagonist for the Modulation of Motor Dysfunction.

  2023cites this paper
• Amyloid-mimicking toxic nanofibers generated via self-assembly of dopamine.

  2022cites this paper
• Anticancer efficacy of endo- and exogenous potent ligands acting at dopaminergic receptor-expressing cancer cells.

  2022cites this paper
• Autophagy as a gateway for the effects of methamphetamine: From neurotransmitter release and synaptic plasticity to psychiatric and neurodegenerative disorders.

  2021cites this paper
• Aptamer Applications in Neuroscience

  2021cites this paper
• In Vitro Effect and Mechanism of Action of Ergot Alkaloid Dihydroergocristine in Chemoresistant Prostate Cancer Cells

  2020cites this paper
• Methamphetamine persistently increases alpha-synuclein and suppresses gene promoter methylation within striatal neurons.

  2019cites this paper
• Modulation of dopamine D1 receptors via histamine H3 receptors is a novel therapeutic target for Huntington's disease

  2019cites this paper
• Paper-Based Electrochemical Biosensors for Point-of-Care Testing of Neurotransmitters

  2019cites this paper
• Facile preparation of a collagen-graphene oxide composite: A sensitive and robust electrochemical aptasensor for determining dopamine in biological samples.

  2019cites this paper
• Physiological and Functional Basis of Dopamine Receptors and Their Role in Neurogenesis: Possible Implication for Parkinson’s disease

  2018cites this paper
• Interdependency Between Autophagy and Synaptic Vesicle Trafficking: Implications for Dopamine Release

  2018cites this paper
• All-inorganic perovskite quantum dot/TiO2 inverse opal electrode platform: stable and efficient photoelectrochemical sensing of dopamine under visible irradiation.

  2018cites this paper
• Heterómeros de receptores de dopamina d1 y de histamina h3 como potenciales dianas terapéuticas en trastornos adictivos y enfermedades neurodegenerativas

  2018cites this paper
• Epigenetic Effects Induced by Methamphetamine and Methamphetamine-Dependent Oxidative Stress

  2018cites this paper
• 20 Don ’ t Take Away My P : Phosphatases as Therapeutic Targets in Huntington ’ s Disease

  2018cites this paper
• Dopamine: Functions, Signaling, and Association with Neurological Diseases

  2018cites this paper
• Quantitative SERS Detection of Dopamine in Cerebrospinal Fluid by Dual-Recognition-Induced Hot Spot Generation.

  2018cites this paper
• Increased osteopontin expression and mitochondrial swelling in 3-nitropropionic acid-injured rat brains.

  2017cites this paper
• Increased insula-putamen connectivity in X-linked dystonia-parkinsonism☆

  2017cites this paper
• Selective Vulnerability of Striatal D2 versus D1 Dopamine Receptor-Expressing Medium Spiny Neurons in HIV-1 Tat Transgenic Male Mice

  2017cites this paper
• What Are Positive Results of Stem Cell Therapies

  2017cites this paper
• Mitochondrial fragmentation in neuronal degeneration: Toward an understanding of HD striatal susceptibility.

  2017cites this paper
• Mechanistic insights into neuronal oscillatory activity in the dopamine-intact and dopamine-depleted primary motor cortex

  2017cites this paper
• Boron-doped carbon nanotubes with uniform boron doping and tunable dopant functionalities as an efficient electrocatalyst for dopamine oxidation reaction

  2017cites this paper
• Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity

  2017cites this paper
• Targeting Phytochemical Driver in AC/cAMP/PKA/CREB Activation: The Next Frontier for Alleviating Huntington’s Type Neurodegenerative Disorders in 3-NP Animal Model: A Complete Review

  2017cites this paper
• Cellular and Molecular Mechanisms of Neuronal Dysfunction in Huntington's Disease

  2017cites this paper
• Plants-Derived Neuroprotective Agents: Cutting the Cycle of Cell Death through Multiple Mechanisms

  2017cites this paper
• Self-reported impulsivity in Huntington’s disease patients and relationship to executive dysfunction and reward responsiveness

  2017cites this paper
• Dopamine exacerbates mutant Huntingtin toxicity via oxidative-mediated inhibition of autophagy in SH-SY5Y neuroblastoma cells: Beneficial effects of anti-oxidant therapeutics.

  2016cites this paper
• Nrf2-ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases.

  2016cites this paper
• Aberrant self-grooming as early marker of motor dysfunction in a rat model of Huntington's disease.

  2016cites this paper
• Altered Neural Synchronies Underlying Cognitive Deficits in a Transgenic Mouse Model of Huntington’s Disease

  2016cites this paper
• Effects of Methylphenidate and Atomoxetine on Development of the Brain

  2016cites this paper
• The Role of the Dopamine D1-D2 Receptor Heteromer in Brain Reward Function: Relevance to Drug Addiction and Depression

  2015cites this paper
• Redox cycling behavior of individual and binary mixtures of catecholamines at gold microband electrode arrays.

  2015cites this paper
• Dissecting Dopamine D2 Receptor Signaling

  2015cites this paper
• Neuroprotection by Saponins

  2015cites this paper
• Huntington's disease: an update of therapeutic strategies.

  2015cites this paper
• Action selection in the striatum : implications for Huntington's disease

  2015cites this paper
• Expanding the Neuroanalytical Toolkit: Electrochemical Measurements of Neurotransmitters Using Poly(3,4-Ethylenedioxythiophene) Conducting Polymer Materials

  2015cites this paper
• Improvement of Mitochondrial Function by Paliperidone Attenuates Quinolinic Acid-Induced Behavioural and Neurochemical Alterations in Rats: Implications in Huntington’s Disease

  2014cites this paper
• PROFOUND AND SELECTIVE DECREASE OF DENDRITIC SPINES IN THE NUCLEUS ACCUMBENS OF ETHANOL DEPENDENT RATs

  2014cites this paper
• Revision of the Classical Dopamine D2 Agonist Pharmacophore Based on an Integrated Medicinal Chemistry, Homology Modelling and Computational Docking Approach

  2014cites this paper
• Wireless Neurophysiology For The Study Of Behavior In Health And Disease

  2014cites this paper
• The role of dopamine in Huntington's disease.

  2014cites this paper
• Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington's disease

  2014cites this paper
• Dopamiinergilise süsteemi valkude diferentsiaalne ekspressioon Wfs1-puudulike hiirte dorsaalses striaatumis

  2014cites this paper
• Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease.

  2014cites this paper
• Human Dopamine Receptors Interaction Network (DRIN): a systems biology perspective on topology, stability and functionality of the network.

  2014cites this paper
• Neurological Diseases and Stem Cell Therapy

  2013cites this paper
• Chemically synthesized graphene for electrochemical biosensing.

  2013cites this paper
• Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility

  2013cites this paper
• Towards understanding region-specificity of triplet repeat diseases: coupled immunohistology and mass spectrometry imaging.

  2013cites this paper
• Changes in brainstem serotonergic and dopaminergic cell populations in experimental and clinical Huntington's disease.

  2013cites this paper
• Sodium dodecyl sulfate-modified electrochemical paper-based analytical device for determination of dopamine levels in biological samples.

  2012cites this paper
• Structural plasticity of the serotonergic and dopaminergic systems : a multidisciplinary approach

  2012cites this paper
• Don’t Take Away My P: Phosphatases as Therapeutic Targets in Huntington’s Disease

  2012cites this paper
• Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: A multimodal imaging study

  2011cites this paper
• Identification and localization of neuron-specific isoform of TAF 1 in rat brain : implications for neuropathology of DYT 3 dystonia

  2011cites this paper
• DOPAMINE RECEPTOR SUBTYPES, IP3, cAMP AND cGMP FUNCTIONAL REGULATION IN PARKINSONISM INDUCED BY UNILATERAL INFUSION OF ROTENONE IN RATS: RECOVERY WITH BONE MARROW CELLS, SEROTONIN AND GABA SUPPLEMENTATION

  2011cites this paper
• Huntington’s Disease and Striatal Signaling

  2011cites this paper
• The Physiology, Signaling, and Pharmacology of Dopamine Receptors

  2011cites this paper
• Changes in striatal procedural memory coding correlate with learning deficits in a mouse model of Huntington disease

  2011cites this paper
• Experimental models of HD and reflection on therapeutic strategies.

  2011cites this paper
• Identification and localization of a neuron-specific isoform of TAF1 in rat brain: implications for neuropathology of DYT3 dystonia.

  2011cites this paper
• Oxidation chemistry of catecholamines and neuronal degeneration: an update.

  2011cites this paper
• Acute and long‐term response of dopamine nigrostriatal synapses to a single, low‐dose episode of 3‐nitropropionic acid‐mediated chemical hypoxia

  2011cites this paper
• Striatal-Enriched Protein Tyrosine Phosphatase Expression and Activity in Huntington's Disease: A STEP in the Resistance to Excitotoxicity

  2011cites this paper
• Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy.

  2011cites this paper
• Neuroprotective Effects of White Tea Against Oxidative Stress-Induced Toxicity in Striatal Cells

  2011cites this paper
• The paradigm of Huntington’s disease: Therapeutic opportunities in neurodegeneration

  2011cites this paper
• A concise synthesis of tetrabenazine: an intramolecular aza-Prins-type cyclization via oxidative C-H activation.

  2011cites this paper
• Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease.

  2011cites this paper
• Molecular mechanisms and potential therapeutical targets in Huntington's disease.

  2010cites this paper
• Estudio de los procesos activadores de la patologia en la enfermedad de Huntington: Alteraciones en la plasticidad sinaptica y perspectivas terapeuticas

  2010cites this paper
• Tetrabenazine is neuroprotective in Huntington's disease mice

  2010cites this paper
• Differential vulnerability of neurons in Huntington’s disease: the role of cell type‐specific features

  2010cites this paper
• Estudio de las vías de supervivencia y muerte neuronal en modelos de la enfermedad de Huntington

  2010cites this paper
• Mitochondria in Huntington's disease.

  2010cites this paper
• Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease.

  2010cites this paper
• Basal ganglia functions in language - the example of Huntington's disease / eingereicht von Nicole Christine Berchtold

  2010cites this paper
• Mitochondrial-associated metabolic changes and neurodegeneration in Huntington's disease - from clinical features to the bench.

  2010cites this paper
• Cyclosporine A Attenuates 3-Nitropropionic Acid–Induced Huntington-Like Symptoms in Rats: Possible Nitric Oxide Mechanism

  2010cites this paper
• Huntington's disease.

  2010cites this paper
• Dopamine and Glutamate in Huntington's Disease: A Balancing Act

  2010cites this paper
• Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium.

  2010cites this paper
• Hyperdopaminergic Status in Experimental Huntington Disease

  2010cites this paper
• Huntington’s disease: pathogenesis to animal models

  2010cites this paper